Specialised pro-resolving mediators (SPMs) are bioactive lipid mediators enzymatically derived from omega-3 fatty acids (EPA, DHA) and arachidonic acid that actively orchestrate the resolution phase of inflammation. Unlike anti-inflammatories that merely suppress inflammatory signals, SPMs execute a coordinated programme: terminating neutrophil recruitment, promoting efferocytosis of apoptotic cells, converting M1 macrophages to M2 macrophages, closing vascular permeability, and reducing pain signalling. The four major families—lipoxins, resolvins, maresins, and protectins—bind to specific G-protein coupled receptors to initiate active resolution rather than passive decay of inflammation.
Think of inflammation like a construction site demolition crew that's been called in to clear damaged tissue. The demolition crew (neutrophils, pro-inflammatory cytokines) arrives, breaks down debris, and creates controlled chaos. But here's the problem: demolition crews don't clean up after themselves or rebuild. They just destroy. Without SPMs, the demolition crew keeps working indefinitely—imagine a construction site where the demolition phase never ends, rubble piles up, and no rebuilding begins.
SPMs are the site foreman who arrives, blows the whistle, sends the demolition crew home, brings in the cleanup crew (M2 macrophages) to remove debris via efferocytosis, closes off the perimeter fencing (vascular permeability), and signals the reconstruction team to start work. The foreman doesn't fight the demolition crew or suppress their tools—they actively redirect operations to the next phase. But here's the critical detail: the foreman can't appear without raw materials. If you haven't delivered omega-3 fatty acids to the job site, the foreman simply doesn't exist. The eicosanoid class switch is like changing the factory's production line from making demolition equipment (prostaglandins, leukotrienes) to making reconstruction signals (SPMs)—but only when the right substrate arrives.
SPM biosynthesis requires the eicosanoid class switch, where COX-2 undergoes post-translational modification:
-
COX-2 modification: Acetylation (by aspirin) or S-nitrosylation (by nitric oxide) changes COX-2's enzymatic activity from producing pro-inflammatory prostaglandins to producing lipid precursors for SPMs
-
Substrate-specific pathways:
-
Receptor binding and cellular actions:
- RvD1 → ALX-FPR2 receptor on neutrophils and macrophages → ↓ NF-κB → stop neutrophil infiltration, enhance efferocytosis
- RvE1 → ChemR23 receptor → activate M2 macrophages, reduce TRPV1 pain signalling
- MaR1 → LGR6 receptor → promote tissue regeneration, reduce neutrophil recruitment
- LXA4 → ALX-FPR2 → block NF-kB translocation, stabilize HIF-1
- PD1 → GPR37 receptor → neuroprotection, reduce microglial activation
-
Efferocytosis enhancement: SPMs upregulate phosphatidylserine receptors on macrophages, increase TGF-beta and IL-10 secretion, facilitate non-inflammatory clearance of apoptotic cells
-
Vascular effects: SPMs reduce VCAM-1 and selectin expression on endothelium, close tight junctions, decrease edema and leukocyte extravasation
-
Pain modulation: Direct inhibition of TRPV1 channels, reduction of substance P, decreased dorsal root ganglion sensitization
graph TD
A["Omega-3 FA: EPA/DHA"] --> B[COX-2 Acetylation/S-nitrosylation]
B --> C[Eicosanoid Class Switch]
C --> D[15-LOX/5-LOX Production]
D --> E[SPM Biosynthesis]
E --> F[Resolvins]
E --> G[Maresins]
E --> H[Protectins]
E --> I[Lipoxins]
F --> J[ALX/FPR2 & ChemR23 Receptors]
G --> K[LGR6 Receptor]
H --> L[GPR37 Receptor]
I --> J
J --> M["↓ Neutrophil Infiltration"]
J --> N["↑ M1→M2 Conversion"]
J --> O["↑ Efferocytosis"]
K --> P["↑ Tissue Regeneration"]
L --> Q[Neuroprotection]
M --> R[Active Resolution]
N --> R
O --> R
P --> R
Q --> R
R --> S[Close Vascular Permeability]
R --> T[Reduce Pain Signaling]
R --> U[Clear Cellular Debris]
SPMs represent the missing resolution phase in chronic inflammatory conditions where standard anti-inflammatory approaches fail. This connects directly to Metamodel 5 (intervention strategies): conventional NSAIDs and corticosteroids suppress inflammation but block SPM production by inhibiting COX-2 and 5-LOX—they prevent both fire and firefighters.
Clinical applications by condition:
-
Chronic pain/neuropathic pain: DHA 6g daily increases resolvin D-series production, reduces TRPV1 sensitization, decreases pain signalling in dorsal root ganglia. Clinical trials show 30-50% pain reduction in diabetic neuropathy after 12 weeks of high-dose DHA.
-
Wound healing: Critical timing protocol: NO omega-3 supplementation for first 7 days post-injury to allow necessary inflammatory phase (neutrophil recruitment, debris clearance). Begin omega-3 supplementation day 8-10 to promote SPM production and transition to proliferative phase. Violating this timing delays healing.
-
Inflammatory bowel disease: RvD1 and MaR1 reduce intestinal neutrophil infiltration, enhance M2 macrophages in lamina propria, restore gut barrier function. SPM deficiency (low omega-3 intake, genetic 15-LOX variants) correlates with treatment-resistant IBD.
-
Metabolic syndrome/obesity: SPM production in adipose tissue converts pro-inflammatory M1 adipose tissue macrophages to M2 phenotype, reduces metaflammation. Low SPM:leukotriene ratio predicts insulin resistance progression.
-
Depression/neuroinflammation: Brain-specific SPMs (neuroprotectin D1) reduce microglia activation, protect hippocampal neurogenesis. Low plasma RvD1 (<200 pg/mL) correlates with treatment-resistant depression.
Evolutionary mismatch: Hunter-gatherer omega-3:omega-6 ratio of ~1:1 ensured adequate SPM substrate availability. Modern Western diet (1:20 ratio) creates SPM deficiency despite normal inflammatory initiation—all demolition, no reconstruction. This explains why chronic inflammation persists despite tissue damage resolution.
Biomarker thresholds:
- Plasma RvD1 >300 pg/mL = adequate resolution capacity
- Omega-3 index >8% = sufficient substrate for SPM biosynthesis
- LTB4:RvD1 ratio <10:1 = balanced inflammation-resolution
Intervention strategy: SPM production cannot occur without substrate—supplementing aspirin or anti-inflammatories without omega-3 fails. The selfish immune system prioritizes immediate inflammatory defence over long-term resolution when substrate is scarce.
- Four SPM families: lipoxins (from arachidonic acid), resolvins (E-series from EPA, D-series from DHA), maresins (from DHA), protectins (from DHA)
- Produced via eicosanoid class switch when COX-2 is acetylated or S-nitrosylated, switching from pro-inflammatory to pro-resolving lipid mediator synthesis
- DHA at 6g daily (approximately 12 standard fish oil capsules) required for therapeutic resolvin production in chronic pain
- Bind to specific GPCRs: RvD1 → ALX-FPR2, RvE1 → ChemR23, MaR1 → LGR6, PD1 → GPR37
- Promote efferocytosis by upregulating phosphatidylserine receptors on macrophages, enabling clearance of 10-20 apoptotic cells per macrophage
- Convert M1 macrophages to M2 macrophages phenotype, reducing TNF-α, IL-1β, IL-6 while increasing IL-10, TGF-beta
- Blocked by NSAIDs (inhibit COX-2) and corticosteroids (inhibit phospholipase A2)—standard anti-inflammatories prevent both inflammation AND resolution
- Timing critical in wound healing: NO omega-3 first 7 days post-injury (allow inflammatory phase), BEGIN omega-3 day 8-10 (promote resolution phase)
- SPM metabolic inactivation via eicosanoid oxidoreductase and dehydrogenases limits duration of action to hours (unlike chronic inflammatory signals)
- Omega-3 index <4% = insufficient substrate for SPM biosynthesis regardless of enzymatic capacity
- Plasma RvD1 concentrations: <200 pg/mL associated with chronic pain, >300 pg/mL indicates adequate resolution capacity
- Aspirin at 81mg daily enables aspirin-triggered resolvins (AT-RvD1, AT-RvE1) with 10-fold greater potency than native resolvins
- Resolvins — One of four SPM families, divided into E-series (EPA-derived) and D-series (DHA-derived), bind ALX/FPR2 and ChemR23 receptors
- Lipoxins — Arachidonic acid-derived SPMs, first discovered resolution mediators, bind ALX/FPR2 to block neutrophil recruitment
- Maresins — DHA-derived SPMs that promote tissue regeneration via LGR6 receptor and enhance M2 macrophage efferocytosis
- Protectins — DHA-derived neuroprotective SPMs (especially neuroprotectin D1 in brain), bind GPR37 to reduce microglial activation
- Omega-3 fatty acids — Essential substrates for SPM biosynthesis; without EPA/DHA availability, resolution cascade cannot occur
- DHA — Primary precursor for D-series resolvins, maresins, and protectins; comprises 30% of brain mass and 50% neuronal membrane
- EPA — Substrate for E-series resolvins via 5-LOX pathway, critical for peripheral tissue resolution
- Arachidonic acid — Omega-6 precursor for lipoxins (pro-resolving) and prostaglandins (pro-inflammatory) depending on enzymatic pathway
- Eicosanoid class switch — Enzymatic transition from pro-inflammatory (PGE2, LTB4) to pro-resolving (SPM) lipid mediator production when COX-2 is modified
- COX-2 — When acetylated (aspirin) or S-nitrosylated (NO), shifts from prostaglandin synthesis to SPM precursor production
- 15-LOX — Key enzyme converting DHA to D-series resolvins and maresins, polymorphisms reduce SPM production capacity
- 5-LOX — Converts EPA to E-series resolvins and arachidonic acid to lipoxins, also produces pro-inflammatory LTB4 from AA
- Efferocytosis — SPM-enhanced macrophage engulfment of apoptotic neutrophils and cellular debris, essential for resolution completion
- M1 macrophages — Pro-inflammatory phenotype actively converted to M2 by SPMs through SOCS1/SOCS3 upregulation and NF-κB inhibition
- M2 macrophages — Pro-resolution phenotype promoted by SPMs, secrete IL-10 and TGF-beta, clear debris via efferocytosis
- Neutrophils — SPMs terminate neutrophil infiltration by blocking CXCR2/CXCR4 signaling and reducing endothelial adhesion molecule expression
- Vascular permeability — SPMs close endothelial gaps by upregulating tight junction proteins (ZO-1, occludin) and reducing VEGF signaling
- NSAIDs — Block SPM production by inhibiting COX-2 and 5-LOX, explaining why chronic NSAID use delays wound healing and perpetuates inflammation
- Aspirin — At low doses (81mg) acetylates COX-2 to produce aspirin-triggered resolvins (AT-SPMs) with enhanced potency
- Wound healing — SPM production marks transition from inflammatory to proliferative phase; timing omega-3 supplementation is critical
- Neuropathic pain — DHA 6g daily produces resolvins that inhibit TRPV1 channels and reduce dorsal root ganglion sensitization
- Resolution of inflammation — SPMs are the molecular executors of active resolution, distinct from passive inflammation decay
- Chronic pain — SPM deficiency (low omega-3 intake, enzymatic polymorphisms) perpetuates pain signaling despite tissue healing
- Chronic inflammation — Results from resolution failure, not excessive inflammation; low SPM:leukotriene ratio is mechanistic driver
- TRPV1 — Nociceptive channel directly inhibited by RvE1, reducing pain signal transmission in dorsal root ganglia
- NF-kB — Pro-inflammatory transcription factor blocked by SPM-ALX/FPR2 signaling, preventing cytokine gene transcription
- IL-10 — Anti-inflammatory cytokine upregulated by SPM-activated M2 macrophages during efferocytosis
- Metaflammation — Chronic metabolic inflammation in adipose tissue resolved by SPMs converting M1 to M2 adipose tissue macrophages
- Inflammatory bowel disease — SPM deficiency correlates with treatment resistance; RvD1 supplementation reduces colonic neutrophil infiltration
- Depression — Low plasma RvD1 associated with treatment-resistant depression via unresolved neuroinflammation and microglial activation
- Microglia — Brain-resident macrophages regulated by neuroprotectin D1, which reduces pro-inflammatory activation and promotes neuroprotection
- Hippocampus — High DHA requirements for SPM-mediated neurogenesis protection and synaptic remodeling during stress recovery
- Module 1 — SPMs introduced as resolution mediators in immune system function and inflammatory cascade
- Module 5 — SPM-based intervention strategies for chronic inflammatory conditions, wound healing protocols, and omega-3 supplementation timing